Molecular Examination of Differentially Expressed Genes in the Brains of Experimental Autoimmune Encephalomyelitis Mice Post Herceptin Treatment

References

• Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–1517. doi:10.1016/S0140-6736(08)61620-7
   PubMed Web of Science ®Google Scholar
• Trapp BD, Nave KA. Multiple sclerosis: an immune or neurodegenerative disorder? Annu Rev Neurosci. 2008;31:247–269. doi:10.1146/annurev.neuro.30.051606.094313
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain. 2005;128(11):2705–2712. doi:10.1093/brain/awh641
   PubMed Web of Science ®Google Scholar
• De Sa JC, Airas L, Bartholome E, et al. Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice. Ther Adv Neurol Disord. 2011;4(3):139–168. doi:10.1177/1756285611403646
   PubMedGoogle Scholar
• Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: pathogenesis, symptoms, diagnoses and cell-based therapy. Cell J. 2017;19(1):1–10. doi:10.22074/cellj.2016.4867
   PubMed Web of Science ®Google Scholar
• Fassbender K, Schmidt R, Mössner R, et al. Mood disorders and dysfunction of the hypothalamic-pituitary-adrenal axis in multiple sclerosis: association with cerebral inflammation. Arch Neurol. 1998;55(1):66–72. doi:10.1001/archneur.55.1.66
   PubMedGoogle Scholar
• Nakajima H, Hosokawa T, Sugino M, et al. Visual field defects of optic neuritis in neuromyelitis optica compared with multiple sclerosis. BMC Neurol. 2010;10(1):45. doi:10.1186/1471-2377-10-45
   PubMedGoogle Scholar
• Sakai RE, Feller DJ, Galetta KM, Galetta SL, Balcer LJ. Vision in multiple sclerosis: the story, structure-function correlations, and models for neuroprotection. J Neuroophthalmol. 2011;31(4):362–373. doi:10.1097/WNO.0b013e318238937f
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society advisory committee on clinical trials of new agents in multiple sclerosis. Neurology. 1996;46(4):907–911. doi:10.1212/wnl.46.4.907
   PubMed Web of Science ®Google Scholar
• Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221–1231. doi:10.1016/S0140-6736(02)08220-X
   PubMed Web of Science ®Google Scholar
• Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol. 2004;3(2):104–110. doi:10.1016/s1474-4422(03)00663-x
   PubMed Web of Science ®Google Scholar
• Muñoz-Culla M, Irizar H, Otaegui D. The genetics of multiple sclerosis: review of current and emerging candidates. Appl Clin Genet. 2013;6:63–73. doi:10.2147/TACG.S29107
   PubMedGoogle Scholar
• McCarthy DP, Richards MH, Miller SD. Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol Biol. 2012;900:381–401. doi:10.1007/978-1-60761-720-4_19
   PubMedGoogle Scholar
• Koprivica V, Cho KS, Park JB, et al. EGFR activation mediates inhibition of axon regeneration by myelin and chondroitin sulfate proteoglycans. Science. 2005;310(5745):106–110. doi:10.1126/science.1115462
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Godolphin W, Jones LA, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–712. doi:10.1126/science.2470152
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344:783–792. doi:10.1056/NEJM200103153441101
   PubMed Web of Science ®Google Scholar
• Carter P, Presta L, Gorman CM, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA. 1992;89(10):4285–4289. doi:10.1073/pnas.89.10.4285
   PubMed Web of Science ®Google Scholar
• Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–1684. doi:10.1056/NEJMoa052122
   PubMed Web of Science ®Google Scholar
• Douglas MR, Morrison KC, Jacques SJ, et al. Off-target effects of epidermal growth factor receptor antagonists mediate retinal ganglion cell disinhibited axon growth. Brain 132. 2009;132:3102–3121. doi:10.1093/brain/awp240
   PubMed Web of Science ®Google Scholar
• Gonzalez-Perez O, Quiñones-Hinojosa A. Dose-dependent effect of EGF on migration and differentiation of adult subventricular zone astrocytes. Glia. 2010;58(8):975–983. doi:10.1002/glia.20979
   PubMed Web of Science ®Google Scholar
• Al-Ani MR, Raju TK, Hachim MY, et al. Rituximab prevents the development of experimental autoimmune encephalomyelitis (EAE): comparison with prophylactic, therapeutic or combinational regimens. J Inflamm Res. 2020;13:151–164. doi:10.2147/JIR.S243514
   PubMed Web of Science ®Google Scholar
• Elemam NM, Hachim MY, Hannawi S, Maghazachi AA. Differentially expressed genes of natural killer cells can distinguish rheumatoid arthritis patients from healthy controls. Genes (Basel). 2020;11(5):492. doi:10.3390/genes11050492
   PubMed Web of Science ®Google Scholar
• Goldschmidt C, McGinley MP. Advances in the treatment of multiple sclerosis. Neuro Clin. 2001;39(1):21–33. doi:10.1016/j.ncl.2020.09.002
   Google Scholar
• Förster M, Küry P, Aktas O, et al. Managing risks with immune therapies in multiple sclerosis. Drug Safety. 2019;42(5):633–647. doi:10.1007/s40264-018-0782-8
   PubMed Web of Science ®Google Scholar
• Handunnetthi L, Ramagopalan SV, Ebers GC. Multiple sclerosis, vitamin D, and HLA-DRB1*15. Neurology. 2010;74(23):1905–1910. doi:10.1212/WNL.0b013e3181e24124
   PubMed Web of Science ®Google Scholar
• Irizar H, Muñoz-Culla M, Zuriarrain O, et al. HLA-DRB1*15:01 and multiple sclerosis: a female association? Mult Scler. 2012;18(5):569–577. doi:10.1177/1352458511426813
   PubMed Web of Science ®Google Scholar
• Levy YA, Fainberg KM, Amidror T, Regev K, Auriel E, Karni A. High and dysregulated secretion of epidermal growth factor from immune cells of patients with relapsing-remitting multiple sclerosis. J Neuroimmunol. 2013;257(1–2):82–89. doi:10.1016/j.jneuroim.2013.01.012
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.3798106
   PubMed Web of Science ®Google Scholar
• Ménard S, Pupa M, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER in cancer. Oncogene 22. 2003;22:6570–6578. doi:10.1038/sj.onc.1206779
   PubMed Web of Science ®Google Scholar
• Klapper LN, Waterman H, Sela M, Yarden Y. Tumor-inhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res. 2000;60(13):3384–3388.
   PubMed Web of Science ®Google Scholar
• Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med. 2000;6(4):443–446. doi:10.1038/74704
   PubMed Web of Science ®Google Scholar
• Arnould L, Gelly M, Penault-Llorca F, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006;94(2):259–267. doi:10.1038/sj.bjc.6602930
   PubMed Web of Science ®Google Scholar
• Shak S. Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group. Semin Oncol. 1999;26(4 Suppl 12):71–77.
   PubMedGoogle Scholar
• Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol. 2007;18(6):977–984. doi:10.1093/annonc/mdl475
   PubMed Web of Science ®Google Scholar
• Abdulkhaleq LA, Assi MA, Abdullah R, Zamri-Saad M, Taufiq-Yap YH, Hezmee MNM. The crucial roles of inflammatory mediators in inflammation: a review. Vet World. 2018;11(5):627–635. doi:10.14202/vetworld.2018.627-635
   PubMed Web of Science ®Google Scholar
• Gasque P, Dean YD, McGreal EP, VanBeek J, Morgan BP. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology. 2000;49(1–2):171–186. doi:10.1016/s0162-3109(00)80302-1
   PubMedGoogle Scholar
• Levi‐Strauss M, Mallat M. Primary cultures of murine astrocytes produce C3 and factor B, two components of the alternative pathway of complement activation. J Immunol. 1987;139(7):2361–2366.
   PubMed Web of Science ®Google Scholar
• Morgan BP, Gasque P. Expression of complement in the brain: role in health and disease. Immunol Today. 1996;17(10):461–466. doi:10.1016/0167-5699(96)20028-f
   PubMedGoogle Scholar
• Lumsden CE. The immunogenesis of the multiple sclerosis plaque. Brain Res. 1997;28(3):365–390. doi:10.1016/0006-8993(71)90052-7
   Google Scholar
• Mead RJ, Singhrao SK, Neal JW, Lassmann H, Morgan BP. The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol. 2002;168(1):458–465. doi:10.4049/jimmunol.168.1.458
   PubMed Web of Science ®Google Scholar
• Mead RJ, Neal JW, Griffiths MR, et al. Deficiency of the complement regulator CD59a enhances disease severity, demyelination and axonal injury in murine acute experimental allergic encephalomyelitis. Lab Invest. 2004;84(1):21–28. doi:10.1038/labinvest.3700015
   PubMed Web of Science ®Google Scholar
• Piddlesden SJ, Storch MK, Hibbs M, Freeman AM, Lassmann H, Morgan BP. Soluble recombinant complement receptor 1 inhibits inflammation and demyelination in antibody‐mediated demyelinating experimental allergic encephalomyelitis. J Immunol. 1994;152(11):5477–5484.
   PubMed Web of Science ®Google Scholar
• Szalai AJ, Hu X, Adams JE, Barnum SR. Complement in experimental autoimmune encephalomyelitis revisited: C3 is required for development of maximal disease. Mol Immunol. 2007;44(12):3132–3136. doi:10.1016/j.molimm.2007.02.002
   PubMed Web of Science ®Google Scholar
• Ristori G, Laurenti F, Stacchini P, et al. Serum amyloid A protein is elevated in relapsing-remitting multiple sclerosis. J Neuroimmunol. 1998;88(1–2):9–12. doi:10.1016/s0165-5728(98)00037-x
   PubMed Web of Science ®Google Scholar
• Lee JY, Hall JA, Kroehling L, et al. Serum Amyloid A proteins induce pathogenic Th17 cells and promote inflammatory disease. Cell. 2020;183(7):2036–2039. doi:10.1016/j.cell.2020.12.008
   PubMed Web of Science ®Google Scholar
• Connolly M, Marrelli A, Blades M, et al. Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J Immunol. 2010;184(11):6427–6437. doi:10.4049/jimmunol.0902941
   PubMed Web of Science ®Google Scholar
• Aslam MS, Yuan L. Serpina3n: potential drug and challenges, mini review. J Drug Target. 2020;28(4):368–378. doi:10.1080/1061186X.2019.1693576
   PubMed Web of Science ®Google Scholar
• Haile Y, Carmine-Simmen K, Olechowski C, et al. Granzyme B-inhibitor serpina3n induces neuroprotection in vitro and in vivo. J Neuroinflammation. 2015;12:157. doi:10.1186/s12974-015-0376-7
   PubMed Web of Science ®Google Scholar
• van Noort JM, Bsibsi M, Gerritsen WH, et al. Alphab-crystallin is a target for adaptive immune responses and a trigger of innate responses in preactive multiple sclerosis lesions. J Neuropathol Exp Neurol. 2010;69(7):694–703. doi:10.1097/NEN.0b013e3181e4939c
   PubMed Web of Science ®Google Scholar
• Peferoen LA, Gerritsen WH, Breur M, et al. Small heat shock proteins are induced during multiple sclerosis lesion development in white but not grey matter. Acta Neuropathol Commun. 2015;3:87. doi:10.1186/s40478-015-0267-2
   PubMed Web of Science ®Google Scholar
• Rolin J, Maghazachi AA. Implications of chemokines, chemokine receptors, and inflammatory lipids in atherosclerosis. J Leukoc Biol. 2014;95(4):575–585. doi:10.1189/jlb.1113571
   PubMed Web of Science ®Google Scholar
• Maghazachi AA, Al-Aoukaty A. Chemokines activate natural killer cells through heterotrimeric G-proteins: implications for the treatment of AIDS and cancer. FASEB J. 1998;12:913–924. doi:10.1096/fasebj.12.11.913
   PubMed Web of Science ®Google Scholar
• Rolin J, Maghazachi AA. Implications of chemokine receptors and inflammatory lipids in cancer. Immunotargets Ther. 2013;3:9–18. doi:10.2147/ITT.S32049
   PubMedGoogle Scholar
• Elemam NM, Hannawi S, Maghazachi AA. Role of chemokines and chemokine receptors in rheumatoid arthritis. Immunotargets Ther. 2020;9:43–56. doi:10.2147/ITT.S243636
   PubMed Web of Science ®Google Scholar
• Dhaiban S, Al-Ani M, Elemam NM, Maghazachi AA. Targeting chemokines and chemokine receptors in multiple sclerosis and experimental autoimmune encephalomyelitis. J Inflamm Res. 2020;13:619–633. doi:10.2147/JIR.S270872
   PubMed Web of Science ®Google Scholar
• Baba T, Mukaida N. Role of macrophage inflammatory protein (MIP)-1α/CCL3 in leukemogenesis. Mol Cell Oncol. 2014;1(1):e29899. doi:10.4161/mco.29899
   PubMedGoogle Scholar
• Cui LY, Chu SF, Chen NH. The role of chemokines and chemokine receptors in multiple sclerosis. Int Immunopharmacol. 2020;83:106314. doi:10.1016/j.intimp.2020.106314
   PubMed Web of Science ®Google Scholar
• Zhang GX, Baker CM, Kolson DL, Rostami AM. Chemokines and chemokine receptors in the pathogenesis of multiple sclerosis. Mult Scler. 2000;6(1):3–13. doi:10.1177/135245850000600103
   PubMed Web of Science ®Google Scholar
• Karpus WJ, Lukacs NW, McRae BL, Strieter RM, Kunkel SL, Millerm SD. An important role for the chemokine macrophage inflammatory protein-1 alpha in the pathogenesis of the T cell-mediated autoimmune disease, experimental autoimmune encephalomyelitis. J Immunol. 1995;155(10):5003–5010.
   PubMed Web of Science ®Google Scholar
• Asensio VC, Lassmann S, Pagenstecher A, Steffensen SC, Henriksen SJ, Campbell IL. C10 is a novel chemokine expressed in experimental inflammatory demyelinating disorders that promotes recruitment of macrophages to the central nervous system. Am J Pathol. 1999;154(4):1181–1191. doi:10.1016/S0002-9440(10)65370-9
   PubMed Web of Science ®Google Scholar
• LaFleur AM, Lukacs NW, Kunkel SL, Matsukawa A. Role of CC chemokine CCL6/C10 as a monocyte chemoattractant in a murine acute peritonitis. Mediators Inflamm. 2004;13(5–6):349–355. doi:10.1155/S0962935104000511
   PubMed Web of Science ®Google Scholar
• de la Fuente H, Cibrián D, Sánchez-Madrid F. Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett. 2012;586(18):2897–2905. doi:10.1016/j.febslet.2012.07.032
   PubMed Web of Science ®Google Scholar
• Cardamone G, Paraboschi EM, Soldà G, Duga S, Saarela J, Asselta R. Genetic association and altered gene expression of CYBB in multiple sclerosis patients. Biomedicines. 2018;6(4):117. doi:10.3390/biomedicines6040117
   PubMed Web of Science ®Google Scholar
• Yong VW, Power C, Forsyth P, Edwards DR. Metalloproteinases in biology and pathology of the nervous system. Nat Rev Neurosci. 2001;2(7):502–511. doi:10.1038/35081571
   PubMed Web of Science ®Google Scholar
• Pagenstecher A, Stalder AK, Kincaid CL, Shapiro SD, Campbell IL. Differential expression of matrix metalloproteinase and tissue inhibitor of matrix metalloproteinase genes in the mouse central nervous system in normal and inflammatory states. Am J Pathol. 1998;152(3):729–741.
   PubMed Web of Science ®Google Scholar
• Pagenstecher A, Wussler EM, Opdenakker G, Volk B, Campbell IL. Distinct expression patterns and levels of enzymatic activity of matrix metalloproteinases and their inhibitors in primary brain tumors. J Neuropathol Exp Neurol. 2001;60(6):598–612. doi:10.1093/jnen/60.6.598
   PubMed Web of Science ®Google Scholar
• Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol. 1992;41(1):29–34. doi:10.1016/0165-5728(92)90192-n
   PubMed Web of Science ®Google Scholar
• Gijbels K, Galardy RE, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest. 1994;94(6):2177–2182. doi:10.1172/JCI117578
   PubMed Web of Science ®Google Scholar
• Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol. 1998;44(1):35–46. doi:10.1002/ana.410440110
   PubMed Web of Science ®Google Scholar
• Crocker SJ, Whitmire JK, Frausto RF, et al. Persistent macrophage/microglial activation and myelin disruption after experimental autoimmune encephalomyelitis in tissue inhibitor of metalloproteinase-1-deficient mice. Am J Pathol. 2006;169(6):2104–2116. doi:10.2353/ajpath.2006.060626
   PubMed Web of Science ®Google Scholar
• Rijvers L, Melief MJ, van der Vuurst de Vries RM, et al. The macrophage migration inhibitory factor pathway in human B cells is tightly controlled and dysregulated in multiple sclerosis. Eur J Immunol. 2018;48(11):1861–1871. doi:10.1002/eji.201847623
   PubMed Web of Science ®Google Scholar
• Falcão AM, van Bruggen D, Marques S, et al. Disease-specific oligodendrocyte lineage cells arise in multiple sclerosis. Nat Med. 2018;24(12):1837–1844. doi:10.1038/s41591-018-0236-y
   PubMed Web of Science ®Google Scholar
• McCormack R, Podack ER. Perforin-2/Mpeg1 and other pore-forming proteins throughout evolution. J Leukoc Biol. 2015;98(5):761–768. doi:10.1189/jlb.4MR1114-523RR
   PubMed Web of Science ®Google Scholar
• Chengkai Y, Tang N, Guo H, Zhang J. C-Type lectin receptor dectin-1 suppresses the development of experimental autoimmune encephalomyelitis. J Immunol. 2020;204(1 Supplement):150.19.
   Web of Science ®Google Scholar
• Gasque P, Singhrao SK, Neal JW, et al. The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol. 1998;160(7):3543–3554.
   PubMed Web of Science ®Google Scholar
• Borges L, Hsu ML, Fanger N, Kubin M, Cosman D. A family of human lymphoid and myeloid Ig-like receptors, some of which bind to MHC class I molecules. J Immunol. 1997;159(11):5192–5196.
   PubMed Web of Science ®Google Scholar
• Seyhan AA, Gregory B, Cribbs AP, et al. Novel biomarkers of a peripheral blood interferon signature associated with drug-naïve early arthritis patients distinguish persistent from self-limiting disease course. Sci Rep. 2020;10(1):8830. doi:10.1038/s41598-020-63757-3
   PubMed Web of Science ®Google Scholar
• Hammond TR, Dufort C, Dissing-Olesen L, et al. Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes. Immunity. 2019;50(1):253–271.e6. doi:10.1016/j.immuni.2018.11.004
   PubMed Web of Science ®Google Scholar